Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study

Abstract: Follicular lymphoma (FL) outcomes are influenced by host immune activity. CD20-directed therapy plus programmed cell death 1 inhibition (PD-1i) increases T-cell tumor killing and natural killer cell antibody-dependent cell cytotoxicity. Mounting evidence supports immune priming using PD-1i...

Full description

Saved in:
Bibliographic Details
Main Authors: Allison Barraclough, Sze Ting Lee, Melinda Burgess, Leonid Churilov, Geoff Chong, Denise Lee, Michael Gilbertson, Tineke Fancourt, Kate Manos, David S. Ritchie, Rachel M. Koldej, Andrew M. Scott, Colm Keane, Eliza A. Hawkes
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292500045X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S247395292500045X

Similar Items